Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Yuran Nam currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and 1 distinct art unit, indicating a concentrated prosecution focus. The company's current legal activity is limited to this specific interaction, which simplifies the oversight required for their pending intellectual property. This concentration allows for a very specific and targeted approach to the current patent application.
The busiest examiner for the company is MOREAU, NASHARA LOUISE, who is responsible for the 1 pending office action. Because there is only 1 distinct examiner involved, the firm's current interactions with the USPTO are centralized. This 1 distinct examiner and 1 distinct art unit will be the primary points of contact for the company's current intellectual property efforts. Practitioners should note that this 1 pending office action represents the entirety of the company's current prosecution risk in this technology area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 66.7% | -80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032023 | A Purified Extract Isolated from Agrimonia Coreana Nakai Containing Abundant Amount of Active Ingredient, the Preparation Thereof, the Composition Comprising the Same as an Active Ingredient for Preventing or Treating Inflammation, Allergy and Atopic Dermatitis and the Use Thereof | MOREAU, NASHARA LOUISE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18032023 | A Purified Extract Isolated from Agrimonia Coreana Nakai Containing Abundant Amount of Active Ingredient, the Preparation Thereof, the Composition Comprising the Same as an Active Ingredient for Preventing or Treating Inflammation, Allergy and Atopic Dermatitis and the Use Thereof | MOREAU, NASHARA LOUISE | 1655 | §101§102§112 | Final Rejection | — | Pending | Apr 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialYuran Nam has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nashara Louise Moreau has the most, with 1 of Yuran Nam's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
